{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-107367","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.678992+00:00","generated_at":"2026-05-31T04:15:25.955732+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years","bullets":["Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).","Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.","Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.","Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-107367","json":"https://secwatch.observer/filing/0000950170-24-107367.json","markdown":"https://secwatch.observer/filing/0000950170-24-107367.md","text":"https://secwatch.observer/filing/0000950170-24-107367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/rgnx-20240916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:15:25.955732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97469485d9","claim":"Mitchell Chan was appointed as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..","evidence_excerpt":"On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"ba4fcd8660","claim":"Vittal Vasista resigned as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..","evidence_excerpt":"the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}